Korean J Urol.  2009 Apr;50(4):327-332.

A Multicenter Prospective Study of the Risk Factors Affecting Bone Mineral Density in Korean Patients with Prostate Cancer

• Jung SI
• Kim SO
• Kang TW
• Kwon DD
• Park JY
• Cheon J
• Lee HM
• Hong SJ
• Choi HY
• Ryu SB

Abstract

PURPOSE
Androgen deprivation therapy (ADT) is associated with loss of bone mineral density (BMD). Preexisting bone losses in men with prostate cancer are of great concern because of accelerated bone loss during ADT. We sought to identify the risk factors associated with osteoporosis in Korean patients with prostate cancer who had not received ADT. MATERIALS AND METHODS: Patients who underwent biopsy of the prostate because of a high prostate-specific antigen (PSA) level or a palpable nodule in a digital rectal examination were included in this study. The patients (n=90) were divided into 2 major groups according to biopsy results: the prostate cancer group (group 1, n=41) and non-prostate cancer group (group 2, n=49). The age, body mass index (BMI), lifestyle, testosterone concentration, BMD, and disease variables in prostate cancer were obtained and analyzed prospectively. BMD of the lumbar spine and femoral neck was measured by dual-energy X-ray absorptiometry. RESULTS: In group 1, 41.4% had osteopenia (36.6%) or osteoporosis (4.8%); in group 2, 26.5% had osteopenia (22.4%) or osteoporosis (4.1%). The estimated mean T-score was significantly (p=0.037) lower in group 1 (-0.668+/-1.364) than in group 2 (-0.041+/-1.426). The significant factors correlated with BMD (T-score) in prostate cancer were age (p=0.012), serum testosterone level (p=0.019), and BMI (p=0.004). CONCLUSIONS: BMDs were lower in men with prostate cancer who had not received ADT than in the control group. Consideration should be given to counseling on risk factors and lifestyle issues in prostate cancer patients with old age, low serum testosterone, and slender stature before initiating ADT.

Keyword

Bone density; Osteoporosis; Prostatic neoplasms

MeSH Terms

Absorptiometry, Photon
Biopsy
Body Mass Index
Bone Density
Bone Diseases, Metabolic
Counseling
Digital Rectal Examination
Femur Neck
Humans
Life Style
Male
Osteoporosis
Prospective Studies
Prostate
Prostate-Specific Antigen
Prostatic Neoplasms
Risk Factors
Spine
Testosterone
Prostate-Specific Antigen
Testosterone

Reference

1. Daniell HW, Dunn SR, Ferguson DW, Lomas G, Niazi Z, Stratte PT. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol. 2000. 163:181–186.

2. Berruti A, Dogliotti L, Terrone C, Cerutti S, Isaia G, Tarabuzzi R, et al. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol. 2002. 167:2361–2367.

3. Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, et al. Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology. 1999. 54:607–611.

4. Diamond T, Campbell J, Bryant C, Lynch W. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer. 1998. 83:1561–1566.

5. Ybarra J, Ade R, Romeo JH. Osteoporosis in men: a review. Nurs Clin North Am. 1996. 31:805–813.

6. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am. 1998. 27:349–367.

7. Conde FA, Sarna L, Oka RK, Vredevoe DL, Rettig MB, Aronson WJ. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy. Urology. 2004. 64:335–340.

8. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994. 9:1137–1141.

9. Eriksson S, Eriksson A, Stege R, Carlström K. Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int. 1995. 57:97–99.

10. Maillefert JF, Sibilia J, Michel F, Saussine C, Javier RM, Tavernier C. Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. J Urol. 1999. 161:1219–1222.

11. Smith MR. Osteoporosis during androgen deprivation therapy for prostate cancer. Urology. 2002. 60:79–85.

12. Orwoll ES, Oviatt SK, McClung MR, Deftos LJ, Sexton G. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med. 1990. 112:29–34.

13. McGrath SA, Diamond T. Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. J Urol. 1995. 154:535–536.

14. Townsend MF, Sanders WH, Northway RO, Graham SD Jr. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer. 1997. 79:545–550.

15. Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol. 1997. 157:439–444.

16. Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002. 162:2217–2222.

17. Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996. 144:255–263.

18. Chang YK, Seo HJ, Jin YW, Jeong MS, Sung SH, Park DY, et al. The prevalence and risk factors of osteopenia and osteoporosis in 40-59 year-old male workers. Korean J Occup Environ Med. 2006. 18:130–137.

19. Agarwal MM, Khandelwal N, Mandal AK, Rana SV, Gupta V, Chandra Mohan V, et al. Factors affecting bone mineral density in patients with prostate carcinoma before and after orchidectomy. Cancer. 2005. 103:2042–2052.

20. Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, et al. Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer. J Urol. 2001. 166:1724–1728.

21. Griffin JE, Wilson JD. Fauci AS, Braunwald E, Isselbacher KJ, Wilson J, Martin J, Kasper D, editors. Disorders of testes. Harrison's principles of internal medicine. 1998. 14th ed. New York: McGraw-Hill;2087–2096.

22. Liu H, Paige NM, Goldzweig CL, Wong E, Zhou A, Suttorp MJ, et al. Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Ann Intern Med. 2008. 148:685–701.

23. Yeh SS, Phanumas D, Hafner A, Schuster MW. Risk factors for osteoporosis in a subgroup of elderly men in a Veterans Administration nursing home. J Investig Med. 2002. 50:452–457.

24. Moyad MA. Osteoporosis-Part I: Risk factors and screening. Urol Nurs. 2002. 22:276–279.

25. Stanley HL, Schmitt BP, Poses RM, Deiss WP. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc. 1991. 39:766–771.

26. Ross PD. Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am. 1998. 27:289–301.

27. Burger H, de Laet CE, van Daele PL, Weel AE, Witteman JC, Hofman A, et al. Risk factors for increased bone loss in an elderly population: the Rotterdam study. Am J Epidemiol. 1998. 147:871–879.

28. Melton LJ 3rd, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993. 8:1227–1233.

29. Higano CS. Management of bone loss in men with prostate cancer. J Urol. 2003. 170:S59–S63.

30. Conde FA, Aronson WJ. Risk factors for male osteoporosis. Urol Oncol. 2003. 21:380–383.